ASCO 2020

ASCO Provides Guidance for Resuming Cancer Care During Pandemic
ASCO Provides Guidance for Resuming Cancer Care During Pandemic
Cancer Progression Linked to Increased Risk of Death in Patients with COVID-19
Cancer Progression Linked to Increased Risk of Death in Patients with COVID-19
Study: Maintenance Therapy With Olaparib Extends Survival By Over 1 Year in Patients With Relapsed Ovarian Cancer, BRCA Mutation
Study: Maintenance Therapy With Olaparib Extends Survival By Over 1 Year in Patients With Relapsed Ovarian Cancer, BRCA Mutation
Data Shows a Decline in Cancer-Related Deaths Following Adoption of the Affordable Care Act
Data Shows a Decline in Cancer-Related Deaths Following Adoption of the Affordable Care Act
Avelumab Shows Potential Treating Patients With Rare Gestational Trophoblastic Tumors
Avelumab Shows Potential Treating Patients With Rare Gestational Trophoblastic Tumors
Trastuzumab Deruxtecan Demonstrates Efficacy in Metastatic Breast Cancer
Trastuzumab Deruxtecan Demonstrates Efficacy in Metastatic Breast Cancer
Study: Major Shift in the Treatment of Patients with CLL in the VHA
Study: Major Shift in the Treatment of Patients with CLL in the VHA
Prior Chemotherapy Linked to Increased Risk of Death With COVID-19
Prior Chemotherapy Linked to Increased Risk of Death With COVID-19
Daunorubicin May Produce, Contribute to Long-Term Remission, Survival in Patients with Newly Diagnosed High-Risk/Secondary AML
Daunorubicin May Produce, Contribute to Long-Term Remission, Survival in Patients with Newly Diagnosed High-Risk/Secondary AML
Pembrolizumab May Change Standard of Care for Patients With Certain Type of Colorectal Cancer
Pembrolizumab May Change Standard of Care for Patients With Certain Type of Colorectal Cancer
Study: Immunotherapy Following Chemotherapy Shows Extended Survival of Patients with Advanced Urothelial Cancer
Study: Immunotherapy Following Chemotherapy Shows Extended Survival of Patients with Advanced Urothelial Cancer
Study: Post-Surgery Osimertinib Delays Disease Recurrence in Patients with Localized Non-Small Cell Lung Cancer
Study: Post-Surgery Osimertinib Delays Disease Recurrence in Patients with Localized Non-Small Cell Lung Cancer